In the wake of the COVID-19 pandemic, I think we've all gained experience managing early stage (0-1) HR+ breast cancers with endocrine therapy as a stop-gap until surgery was possible. However, outside of a clinical trial or unusual circumstances, I would not normally consider managing HR+ DCIS non-...